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Abstract: Spinal cord stimulation has seen unprecedented growth in new technology in the
50 years since the first subdural implant. As we continue to grow our understanding of spinal
cord stimulation and relevant mechanisms of action, novel questions arise as to electrical
dosing optimization. Programming adjustment — dose titration — is often a process of trial
and error that can be time-consuming and frustrating for both patient and clinician. In this
report, we review the current preclinical and clinical knowledge base in order to provide
insights that may be helpful in developing more rational approaches to spinal cord stimula
tion dosing. We also provide key conclusions that may help in directing future research into
electrical dosing, given the advent of newer waveforms outside traditional programming
parameters.
Keywords: neural dosing, pharmacology, neuromodulation, spinal cord stimulation,
electrical dosing
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For pain medicine, optimizing the dosage of pharmaceuticals means that the
medication choice and amount, route of administration, and frequency are carefully
titrated to maximize efficacy while minimizing side effects.1–3 Generally, this
means using the lowest effective dose. In intrathecal drug delivery, this concept
has gained traction in that an equivalent or perhaps superior clinical outcome can be
achieved with a substantially lower daily dose of drug.4
Spinal cord stimulation (SCS) is a medical option within interventional pain
medicine. Although used clinically for more than 50 years, SCS has gained a great
deal of interest in recent years, as it represents a drug-free option for ongoing
management of chronic pain, such as back pain, radicular pain, complex regional
pain syndrome (which includes causalgia), peripheral neuropathies, and other
neuropathic pain conditions.5–7 Traditionally, for SCS therapy, electrodes are
implanted in the epidural space overlying the portions of the dorsal column of the
spinal cord that somatotopically correspond to the painful dermatomes of the body.
An electrical current is then delivered to the electrodes by means of an implanted
pulse generator that often includes an implanted battery. The electricity induces
changes in the electrical potential of the cell membranes of axons in the spinal cord,
in many cases generating action potentials that propagate anti- and orthodromically
to modulate neurons in the gray matter of the spinal cord, as well as brain sites. On
Journal of Pain Research 2021:14 2767–2776
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a basic level, this is thought to modulate neural function
within pain pathways in various ways depending on the
pattern of stimulation to help mask or relieve pain. SCS is
often considered successful when pain is reduced by 50%
or more. Importantly, SCS can reduce pain severity suffi
ciently to allow some pain patients to reduce their use of
medications and break free of opioid dependence.8,9
A landmark randomized controlled trial comparing SCS
with conventional medical management showed that the
former provided better leg pain relief, quality of life, and
functional capacity and could be sustained through 24
months.10
In the last decade, innovations in SCS have led to the
development of new electrical waveforms. Where SCS
was once limited to square pulses delivered in
a consistent stream at a set frequency (2–1,200 Hz),
pulse width (1–1,000 microseconds), and amplitude (0–
20 mA), these programming parameters are still com
monly used today, but are now often referred to as “tradi
tional tonic stimulation.” New stimulation patterns and
frequencies now include burst SCS (pulsatile packets of
stimulation with different charge recovery strategies) and
high-frequency SCS, the definition of which is conten
tious: some claim it to have a low range of 1kHz, while
others claim it needs to be >1.2 kHz, the traditional upper
limit of most commercially available implantable pulse
generators, yet others claim it refers only to stimulation
of 5–10kHz. Examples are shown in Figure 1. Highdensity or high-dose SCS, in which longer pulse widths
and/or higher frequencies are used, has also shown clinical
utility.11–14 Beyond just programming parameter changes,
devices that target novel anatomical structures, such as the
dorsal root ganglion, have been approved by regulatory
bodies all over the world.15,16 Multiple detailed
reviews have been published on putative mechanisms of
action specific to these various approaches.17–20 With this
range of interventions and programming strategies avail
able, clinicians must stay abreast of the comprehensive
body of literature supporting each therapeutic approach
to guide selection of the most appropriate therapy for
a given patient. Once a therapy is chosen, similar to
pharmacological treatment, the appropriate electrical
dosage must be prescribed/titrated by programming the
device with the correct number and polarity of active
electrodes along with the appropriate settings for pulse
width, frequency, amplitude, and duty cycling (the percen
tage of “stimulation-on” time).21 This concept is summar
ized in Figure 2.
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Clinical observations and studies have emerged from
the SCS industry and the implanter community that clini
cally meaningful pain relief and avoidance of side effects
may be achieved by minimizing the electrical charge that
is delivered to the neural interface. Clearly, this mirrors the
approach for pharmaceuticals. Unfortunately, the field of
SCS has yet to adequately describe an electrical equivalent
of pharmacokinetics/pharmacodynamics that can be used
as a guide for dosing. Instead, dosing decisions are usually
empirical, based on observations in the programming
clinic and feedback from the patient. Programming adjust
ments — dose titration — are often a process of trial and
error that can be time-consuming and frustrating for both
patient and clinician. In this report, we review the current
preclinical and clinical knowledge base to provide insights
that may be helpful in developing more rational
approaches to SCS dosing. We also provide key conclu
sions that may help in directing future research into elec
trical dosing.

Insights Gained into Dosing from
Preclinical Research
Tonic Paresthesia-Based SCS
While initially discussed within the context of the gatecontrol theory of pain, there have been significant
advances in understanding the mechanisms of action of
paresthesia-based SCS. Among the best-studied
mechanisms is attenuation of the activity of wide dynamic
range neurons (pathologically activated in chronic pain
states) via increased activity of inhibitory interneurons
through both spinal and supraspinal mediators.22 These
mediators include GABA, glycine, serotonin, and
norepinephrine.22–24 Yakhnitsa et al demonstrated that fol
lowing paresthesia-based SCS in an animal model of pain
ful mononeuropathy, there was a reduction in dorsal horn
neuronal hyperexcitability that corresponded with
improvement in tactile allodynia.25 An additional proposed
mechanism is the reduction of glial cell activation at the
level of the spinal cord. An animal-model study completed
by Sato et al examined the use of paresthesia-based SCS
utilizing sham, 4 Hz, or 60 Hz treatment of varying dura
tions and amplitudes in rats with peripheral nerve injury.26
They found that greater analgesia was seen with 6 hours of
60 Hz than 30 minutes, and that not at 90% amplitude of
motor threshold (energy level at which motor activation
occurs) was significantly more efficacious than 75%. Of
note, 50% of motor activation saw no changes in paw-
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Figure 1 Top: Waveforms for tonic (A), burst (B), and high-frequency (C) SCS, allowing comparison of relative pulse widths, frequencies, and amplitudes. Reprinted with
permission from Reprinted with permission from Taylor and Francis. Ahmed S, Yearwood T, De Ridder D, Vanneste S. Burst and high frequency stimulation: underlying
mechanism of action. Expert Rev Med Devices. 2018;15(1):61–70.67 Bottom: Schematic illustrating pulse width, frequency, and burst variables (A and, B), as well as factors
that create the electrical properties of a single pulse within a waveform (C). Reproduced from Reproduced from Caylor J, Reddy R, Yin S, et al. Spinal cord stimulation in
chronic pain: evidence and theory for mechanisms of action. Bioelectron Med. 2019;5(1):12. Creative Commons license and disclaimer available from: http://creativecom
mons.org/licenses/by/4.0/legalcode.38
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Figure 2 Key parameters in dose programming for dorsal column stimulation.

withdrawal threshold, essentially equivalent to sham treat
ment. The authors also found that there were robust reduc
tions in microglial and astrocyte activation markers
following both 4 Hz and 60 Hz paresthesia-based stimula
tion. These results have recently been replicated in
a spared nerve injury model in rodents using 60 Hz stimu
lation, again showing reductions in microglial activation
and pain responses with application of either minocycline,
a glial inhibitor, or SCS.27

Burst SCS
Burst SCS utilizes a paradigm of pulse trains of high
frequency (typically 500 Hz) stimulation in five 1-milli
second pulses at an overall interburst frequency of 40
Hz.28 This therapy was born of observations that many
neurons in the nervous system fire in phasic or burst
patterns.29 Intracellular recordings of these burst/phasic
firing neurons have shown that the burst firing typically
rides on a plateau of slow calcium-mediated depolariza
tion. Snider et al examined burst signaling within the
visual cortex of a cat model and found that spatially
optimal longer bursts were more effective in eliciting
neuronal responses than shorter spatially nonoptimal
bursts.30 Crosby et al investigated the parameters involved
in burst SCS in a rat model with cervical nerve root injury
and neuropathic pain, and found that pulse number, pulse
width, and amplitude were significantly correlated with
suppression of neuronal firing.31 A comparison to par
esthesia-based SCS in an animal model was done by
Gong et al.32 Rats with spared nerve injury were implanted
and treated with sham, 16 Hz, 60 Hz, and 140 Hz par
esthesia-based frequencies and four burst therapies with
varying burst frequency, pulse frequency, and pulse width.
They found that all but sham and 16 Hz SCS had statisti
cally significant improvement in paw withdrawal
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threshold, and that burst parameters of 2, 3, and 4 were
statistically superior to 60 Hz. Within the burst paradigms,
there was no difference between stimulation frequency,
pulse width, or pulse frequency.
Unique to the targeting of burst SCS to the mediotha
lamic and limbic components of pain processing is
improvement in the affective and emotional components
of pain. Although difficult to study, this has been partially
demonstrated by Meuwissen et al using a rat model com
paring paresthesia-based and burst SCS.33 This study sug
gested that more than paresthesia-based SCS, burst did in
fact modulate the affective–emotional components of pain.
At this time, the effect of burst SCS on the biochemical
mediators of the pain pathway, such as serotonin, norepi
nephrine, or opioids is unknown.

High-Frequency SCS
As opposed to traditional paresthesia-based SCS, paresthe
sia-free SCS uses significantly higher-frequency electrical
impulses (10 kHz) and lower amplitudes, with ultimately
no sensations felt by the patient.34 This combination of
high pulse width and low amplitude ultimately increases
the duty cycle. While overall understanding of the
mechanism of action of paresthesia-free SCS is lacking,
there have been several proposed mechanisms. Linderoth
et al proposed a neuronal blockade, desynchronization of
neural signals, and membrane integration leading to the
equivalent of temporal summation.35 Neuronal blockade
has been somewhat supported by Lee et al, in which an ex
vivo patch clamp of spinal cord neurons demonstrated
suppressed firing with high-frequency stimulation.35 It
has also been theorized that the temperature increases
related to the higher power of high-frequency SCS deliv
ered into the tissue may also be a mechanism of action, or
at the least a factor in lead positioning and programming.
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Energy delivery that is sufficient to induce heating (ie, as
may be observed in kilohertz-frequency waveforms) may
modulate spinal activity to harness the gate-control theory
of pain control via a novel heat mechanism.36,37 Although
theoretical, heating-based SCS therapy would be influ
enced by the percentage of stimulation-on time and tissue
impedance. Changes in complex cerebrospinal fluid
(CSF)–temperature homeostasis can alter cellular function
and metabolism, in addition to vascular function.
Furthermore, it has been hypothesized that temperature
changes affecting heat shock protein that then modulate
neuroinflammation may be an additional mechanism of
action.36,38 The supraspinal effect of paresthesia-free
SCS is unknown at this time, but has been hypothesized
to be negligible, due to the primarily superficial neuronal
tracts affected.34

Insights Gained into Dosing from
Clinical Studies
Subperception SCS
Thompson et al demonstrated significant clinically
equivalent pain reduction compared to baseline at
sequentially decreasing frequencies from 1,000 Hz to 10
Hz.39 At the same time, the pulse width of the stimulating
waveform was increased, maintaining subparesthesia sti
mulation therapy. This study also suggested that high
frequencies are not needed to produce noteworthy sub
paresthesia analgesia in SCS. The clinical results are
compelling, but they are due not so much to frequency
per se, but profoundly more to the technique of field
application, incorporating both area distribution enhance
ment and field vector orientation. Pain relief was 48%–
52% with all frequencies.39

Burst SCS
In nonlinear burst, charge accumulates over exposed tis
sue, increasing incrementally with each successive stimu
latory phase, and is maintained at that level by the
prolonged interphase delay. Some of this charge tends to
drift, especially within the CSF, significantly increasing
the effective pulse width of the compound stimulatory
waveform. As the charge accumulates, it spreads prefer
entially along the surface of the spinal cord much more
than it penetrates the surface to deeper levels, as it follows
the path of least resistance. This effectively enlarges the
surface area of the applied field and affects a much larger
volume of neural elements in the process, thus having
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a larger field of tissue engagement. These multiple depo
larizations, sequentially increasing in number and intensity
throughout the burst train, have powerful global influence
in both orthodromic action potentials to cortical areas and
antidromic action potentials to the dorsal horn and
beyond.40 An early report in patients who had previously
received tonic SCS showed incremental improvements
when using burst stimulation.41 Later, a randomized con
trolled trial showed that 60% of participants had at least
30% pain relief in response to burst SCS vs 51% with
tonic SCS.42
Work by Vesper et al employed the use of duty cycling
in what came to be termed microdosing.43 In these 5
seconds on–5 seconds off and 5 seconds on–10 seconds off
doses, it was concluded that therapy was not compro
mised, and less total energy was required. This work was
expanded by Deer et al, albeit with more nuanced duty
cycle interval programming that involved alternating 30
seconds on with up to 360 seconds off.44 After 6 months,
nearly half the patients selected the 30:360 ratio of stimu
lation and had good therapeutic outcomes.
In these studies, the concept of dosing using the least
possible exposure to SCS therapy built on previous con
cepts described by Miller et al in their attempts to define
neural dosing in terms of total charge delivery per 
second.21 The authors for both the aforementioned
microburst studies chose their settings somewhat arbitra
rily, and considerations of optimal number of pulses per
burst, optimal amplitudes, and intraburst and interburst
frequencies were lacking; however, the underlying
effects on human neurophysiology are being explored
and have been described in recent studies utilizing neu
romonitoring as an objective proxy for postsynaptic
neural effects.45,46 These variables affect both the
device’s battery life and the biological impact of the
applied electrical field, and while some of these neural
effects are being uncovered using human neurophysiolo
gical measures, future studies will continue to build on
this knowledge.

High-Frequency SCS
The literature supports the notion there are minimal
supraspinal effects of high-frequency SCS.47 Specifically,
there is no evidence that evoked compound action poten
tials (ECAPs) are produced by this stimulatory waveform,
and to date there have been no reported PET studies that
would indicate direct supraspinal mechanisms playing
a measurable role.
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Recently, al-Kaisy et al described the use of cascade
programming for high-frequency SCS at their clinic in the
UK.48,49 Specifically, cascade programming is based on
duty cycling sequentially through four bipole contact con
figurations using all eight contacts of the lead (1–2, 3–4,
5–6, and 7–8). Each bipole of one anode and one cathode
is activated for 5 seconds and then deactivated as the next
bipole in the sequence is activated for 5 seconds. As such,
the entire lead is covered in 20 seconds, during which time
each bipole is active for 5 seconds and inactive for 15
seconds. This design mitigates against small lead migra
tion, long reprogramming sessions to search for optimal
targeting, and potential overstimulation. Every 20 seconds,
32 mm is treated in this manner. The choice of a 5-second
activation time was based on in vitro studies of astrocytedepolarization
times
during
external
electrical
50
stimulation, and this fits within the framework of focus
ing on glial cell dynamics as part of the overall stimulation
paradigm. Built within this programming paradigm is the
duty cycling concept such that no region of the cord is
exposed to >5 seconds of stimulation every 20 seconds.
Using cascading in the study, >50% pain reduction was
achieved in back pain for 57% of patients at 6 months and
56% at last follow-up, and 60% or patients with leg pain at
6 months and 59% at last follow-up.48,49
Provenzano et al reported a retrospective review over
the first 12 months after implantation of 42 patients with
a high-frequency SCS device for treatment of neuropathic
pain from a large variety of pain conditions.51
Interestingly, despite impressive trial successes with
a trial:implant ratio of 89%, only 39% of patients contin
ued to have their best pain relief at the same contact
configuration as used in the trial. Additionally, 73% of
patients who used duty cycling (switching between on
and off for set durations) were considered treatment
responders. One patient was noted to have responded
equally well at both the T9/10 and T10/11 disk spaces,
while others required stimulation of multiple areas within
the programming paradigm to achieve suitable relief. Of
note, the recharge burdens reported in this study were
substantial, with an average of 2.1 hours daily. This level
of energy use is a hallmark of high-frequency stimulation
programming strategies, with reported recharge times from
45 minutes to >2.5 hours per day.13,52

ECAP-Controlled Closed-Loop SCS
The ability to measure ECAPs is a more recent advance
ment within the field of neuromodulation that allows for
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both the study and modification of the delivery of SCS;
however their use in neuromodulation devices goes back
to the late 1990s in the cochlear implant field. ECAPs are
the population response of nerve fibers.53 This is achieved
through the measurement of the electrical field created by
the movement of ions across the membrane of the nerve
axon during an action potential from the initial stimulus.54
The neurophysiological recordings can then be used to
determine the recruitment of a subset of fibers in response
to dorsal column stimulation by utilizing nonstimulation
recording electrodes to measure ECAPs. Animal studies
initially demonstrated this in 2012, confirming the theory
that SCS primarily recruits large-diameter Aβ fibers and
that the ECAP amplitude increases with increasing current
level.55 This has also been shown in a human model.56 The
prospective open-label AVALON study using a closedloop SCS device for patients with chronic back and/or
leg pain was published in 2018 and with follow-up in
2020, showing excellent pain relief that was durable over
time.53,57 Importantly, this demonstrated that the device
was able both to deliver treatment and measure ECAP to
adjust therapy by adjusting dorsal column–fiber recruit
ment levels. A randomized controlled study comparing
ECAP-controlled closed-loop SCS with open-loop SCS
by Mekhail et al showed that pain outcomes were better
in the closed-loop group after 3 and 12 months of treat
ment (72% overall VAS reduction at 12 months in the
closed-loop group and 56% reduction in the open-loop
group). Furthermore, patients in the closed-loop group
had ECAP amplitudes that were within the therapeutic
range a much greater proportion of the time than patients
in the open-loop group; however, the proportion of
increased time spent in this paresthesia-inducing window
(12 months closed loop 95%, open loop 48%) did not
equate to an equivalent ratio of pain relief.58 This discre
pancy will need to be explored in future studies.

Dosing in SCS: The Mechanisms
The dose of an administered electrical field to a neural
target is a very complex combination of variables: polarity
of the electrical field; frequency; amplitude; shape of the
stimulatory waveform; effective impedance of spinal tis
sue and impedance of internal elements of the device, both
implantable pulse generator and leads; effective pulse
width; distribution of charge over the targeted area; instan
taneous rate of change of this charge distribution; threedimensional vector properties of the field; and mass and
complexity of neuronal tissue exposed to applied electrical
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fields. In addition, the stimulation-on vs -off ratio, CSF
thickness and other complex spinal anatomy, circulation of
CSF, lead encapsulation, lead positioning, and electrode
configurations affect how much stimulus is delivered to
the spinal target.21,59–64 Changes in any one variable may
affect overall dosing. An anatomically realistic computa
tional model of SCS has been developed and can help
researchers understand the interactions of complex tissue
compartments in terms of impedance.62 It has also been
noted that actual stimulation output may be lower than the
as-programmed stimulation:37 a “governor” function
established by regulatory requirements to maintain safe
levels of electrical stimulation. If unaware of this, clini
cians could dramatically misinterpret the implications of
their programming choices.
The field polarity is either negative (cathode) or posi
tive (anode), and the applied field voltage repels the nega
tive charge from the anode toward the cathode where it
accumulates simultaneously with the positive charge accu
mulating under the anode. This interphase delay is
the period when no electrical charge is moving relative
to the lead contacts of the device. This certainly does not
mean the charge is not undergoing tissue penetration or
slight dispersion in the CSF at the surfaces of exposed
tissue. We have yet to fully understand exactly how the
charge accommodates itself along the surface(s) of the
biological tissue to which it has been applied.59
The shape of the stimulatory waveform represents this
instantaneous variation in field intensity. The recruitment
of neurons under the influence of a sinusoidal waveform
will be quite different from the recruitment expected under
a square waveform. Both these waveforms will recruit
different-size axons or glial elements in a manner different
from an exponential stimulatory phase or a randomly
applied series of square waves of randomly generated
frequencies and amplitudes. It is reasonable to think that
various waveforms could achieve differential tissue
responses in neurons and glial cells. To prove the point,
a very simplistic set of waveforms was applied by Vallejo
et al in an animal model of chronic neuropathic pain.65
They then examined the genomic consequences of these
various waveforms in different types of glial and neuronal
cells to determine differences in transcription and produc
tion of proteins caused by the waveforms that showed
clear differences. While this work helped expand knowl
edge in this field, the glial and neuronal structures exam
ined resided directly below the applied electric fields, and
typical SCS-electrode placement in the spinal canal (T7–
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T10) is not located above the corresponding neuronal and
glial cells’ receptive fields for low-back and leg pain
(lumbar enlargement, T12–L2). This anatomical distance
between electrical field and target tissue must be explored
and accounted for before these preclinical results can be
generalized to the clinical population. The prevalent theme
in work across multiple SCS waveforms is that higher
doses of electricity significantly increase the surface area
of the spinal cord covered by the stimulatory waveform.
Together with the biological and clinical status of the
targeted field, this can greatly influence the efficacy of
the therapy.
PET CT or MRI have been used to image activated
microglia with radioligands targeting the transporter pro
tein TSPO in the spinal cord, and may provide a guide to
determining optimal field targeting for paresthesia-free
stimulatory waveforms.66 The maximal area of neuroin
flammation in the spinal cord may not be located at the
anatomical site determined by paresthesia-guided target
ing. The area of neuroinflammation in the cord of greatest
concern for neuropathic pain is within the gray matter of
the dorsal horn. This is where the multiple areas of neural
circuitries involved in central sensitization and wind-up
phenomena are most likely to occur. Because all SCS is
a surface-related phenomenon, sensory fibers must gain
dorsal exposure to be recruited by the applied electrical
field, and this may require as much as the width of a whole
vertebral body in the lower area of the thoracic spinal
cord. The sensory perception of paresthesia-guided target
ing over the dorsal columns is often removed at a distance
from the region of the dorsal horn where neuroinflamma
tory processes associated with neuropathic pain are con
centrated, as noted previously.
Briefer exposure has a lower risk of overstimulation.
This may explain why the outcomes of the Sunburst study
were not as robust as had been expected and did improve
with decreasing target amplitudes.42 Further studies are
under way to more fully evaluate the use of this technique
and other techniques to reduce stimulation dose. The use
of on–off stimulation patterns has now become prevalent
in all the paresthesia-free waveforms as a means to avoid
potential overstimulation.
Another theme has been to incorporate a global therapy
by combining both orthodromic and antidromic SCS ther
apy. The bursting paradigm creates orthodromic modula
tion at the cortical level, capable of affecting both the
discriminative and affective components of chronic neuro
pathic pain. On the other hand, 10 kHz SCS has not
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specifically demonstrated any direct neurophysiological
supraspinal activity,47 its effects appear to be much more
local, and there is a trend within the industry to promote
the blending of paresthesia-based sensory stimulation with
paresthesia-free stimulation. Because stimulation can be
incremental, with periods of stimulator activation alternat
ing with periods of inactivity (“off” periods), there is
ample time to add a bit of paresthesia-based sensory sti
mulation to distract pain awareness in the hope of bringing
on more rapid pain relief. Paresthesia-free stimulation
tends to be notoriously slow in onset, especially if its
primary modus operandi is local, as it should be for
purposes of safety and durability of therapy. However, in
an industry that developed during the age of paresthesiabased sensory stimulation, it can be culturally burdensome
to wait for the onset of efficacy. There is no rigorous
medical evidence to pursue this approach. Instead, there
is evidence to the contrary. Subjects exposed to conven
tional paresthesia-based therapy fared less well with sub
sequent paresthesia-free therapy during a crossover
clinical trial.42 It should also be noted that blending these
stimulation modalities is at odds with the concept of lower
neural doses, as they often use much higher levels of
energy to interleave or simultaneously stimulate at multi
ple frequencies, pulse widths, and amplitudes. These stra
tegies should not be confused with strategies that attempt
to lower the electrical energy applied to the target tissue.
Another significant difficulty with the concept of blending
paresthesia-free therapy with paresthesia-based therapy is
the inability to separate the true responders from the pla
cebo responders using this programming paradigm. Also,
the effects of antidromic stimulation from paresthesiabased therapy could drastically counteract the effects of
paresthesia-free therapies, as these interactions have not
been adequately studied. Additionally, the combination of
therapies could result in overstimulation, due to neuroplas
ticity and higher energy use. As such, until the nature of
cognitive distraction, potential for placebo response, and
counterproductive potential of paresthesia-based treat
ments if blended with paresthesia-free therapy are under
stood, this integrated trend requires more research.
Each of these trends impact considerably on our
notions of “neural dosing” and must be considered as we
further develop a neural dosing approach to therapy.
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